An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target
Mahil, S. K., Catapano, M., Di Meglio, P., Dand, N., Ahlfors, H., Carr, I. M., Smith, C. H., Trembath, R. C., Peakman, M., Wright, J., Ciccarelli, F. D., Barker, J. N. & Capon, F., 11 Oct 2017, In: Science Translational Medicine. 9, 411, eaan2514.
Research output: Contribution to journal › Article › peer-review